Literature DB >> 10318865

Inducible expression of protein kinase CK2 in mammalian cells. Evidence for functional specialization of CK2 isoforms.

G Vilk1, R B Saulnier, R St Pierre, D W Litchfield.   

Abstract

Protein kinase CK2 (formerly casein kinase II) exhibits elevated expression in a variety of cancers, induces lymphocyte transformation in transgenic mice, and collaborates with Ha-Ras in fibroblast transformation. To systematically examine the cellular functions of CK2, human osteosarcoma U2-OS cells constitutively expressing a tetracycline-regulated transactivator were stably transfected with a bidirectional plasmid encoding either catalytic isoform of CK2 (i.e. CK2alpha or CK2alpha') together with the regulatory CK2beta subunit in order to increase the cellular levels of either CK2 isoform. To interfere with either CK2 isoform, cells were also transfected with kinase-inactive CK2alpha or CK2alpha' (i. e. GK2alpha (K68M) or CK2alpha'(K69M)) together with CK2beta. In these cells, removal of tetracycline from the growth medium stimulated coordinate expression of catalytic and regulatory CK2 subunits. Increased expression of active forms of CK2alpha or CK2alpha' resulted in modest decreases in cell proliferation, suggesting that optimal levels of CK2 are required for optimal proliferation. By comparison, the effects of induced expression of kinase-inactive CK2alpha differed significantly from the effects of induced expression of kinase-inactive CK2alpha'. Of particular interest is the dramatic attenuation of proliferation that is observed following induction of CK2alpha'(K69M), but not following induction of CK2alpha(K68M). These results provide evidence for functional specialization of CK2 isoforms in mammalian cells. Moreover, cell lines exhibiting regulatable expression of CK2 will facilitate efforts to systematically elucidate its cellular functions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10318865     DOI: 10.1074/jbc.274.20.14406

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  The activity of CK2 in the extracts of COS-7 cells transfected with wild type and mutant subunits of protein kinase CK2.

Authors:  I Korn; G Jacob; C C Allende; J E Allende
Journal:  Mol Cell Biochem       Date:  2001-11       Impact factor: 3.396

Review 2.  Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.

Authors:  David W Litchfield
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

3.  Casein kinase 2 beta-subunit is a regulator of bone morphogenetic protein 2 signaling.

Authors:  Beth Bragdon; Shayamala Thinakaran; Oleksandra Moseychuk; Daniel King; Kira Young; David W Litchfield; Nils O Petersen; Anja Nohe
Journal:  Biophys J       Date:  2010-08-04       Impact factor: 4.033

4.  Phosphorylation of RIG-I by casein kinase II inhibits its antiviral response.

Authors:  Zhiguo Sun; Hongwei Ren; Yan Liu; Jessica L Teeling; Jun Gu
Journal:  J Virol       Date:  2010-11-10       Impact factor: 5.103

5.  CK2 interacting proteins: emerging paradigms for CK2 regulation?

Authors:  Mary Ellen K Olsten; Jane E Weber; David W Litchfield
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

6.  Evidence for regulation of mitotic progression through temporal phosphorylation and dephosphorylation of CK2alpha.

Authors:  Nicole A St-Denis; D Richard Derksen; David W Litchfield
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

7.  A large-scale functional RNAi screen reveals a role for CK2 in the mammalian circadian clock.

Authors:  Bert Maier; Sabrina Wendt; Jens T Vanselow; Thomas Wallach; Silke Reischl; Stefanie Oehmke; Andreas Schlosser; Achim Kramer
Journal:  Genes Dev       Date:  2009-03-15       Impact factor: 11.361

8.  A role for CK2alpha/beta in Xenopus early embryonic development.

Authors:  Isabel Dominguez; Junko Mizuno; Hao Wu; Gregory A Imbrie; Karen Symes; David C Seldin
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

9.  Liver mTOR controls IGF-I bioavailability by regulation of protein kinase CK2 and IGFBP-1 phosphorylation in fetal growth restriction.

Authors:  Majida Abu Shehab; Ian Damerill; Tong Shen; Fredrick J Rosario; Mark Nijland; Peter W Nathanielsz; Amrita Kamat; Thomas Jansson; Madhulika B Gupta
Journal:  Endocrinology       Date:  2014-01-17       Impact factor: 4.736

10.  The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development.

Authors:  David Y Lou; Isabel Dominguez; Paul Toselli; Esther Landesman-Bollag; Conor O'Brien; David C Seldin
Journal:  Mol Cell Biol       Date:  2007-10-22       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.